Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ming-Huang Chen

Showing results (171-180 of 183) with videos related to

Pageof 19
Sort By:
Journal of Molecular Medicine (Berlin, Germany)|June 5, 2017
Sequential combination of docetaxel with a SHP-1 agonist enhanced suppression of p-STAT3 signaling and apoptosis in triple negative breast cancer cellsChun-Yu Liu, Kuen-Feng Chen, Tzu-I Chao, et al.
Journal for Immunotherapy of Cancer|April 3, 2020
<i>PRKDC</i>: new biomarker and drug target for checkpoint blockade immunotherapyKien Thiam Tan, Chun-Nan Yeh, Yu-Chan Chang, et al.
EJNMMI Research|May 24, 2019
A phase 0 study of the pharmacokinetics, biodistribution, and dosimetry of <sup>188</sup>Re-liposome in patients with metastatic tumorsShyh-Jen Wang, Wen-Sheng Huang, Chi-Mu Chuang, et al.
Oncotarget|June 20, 2015
Identification of SPHK1 as a therapeutic target and marker of poor prognosis in cholangiocarcinomaMing-Huang Chen, Chueh-Chuan Yen, Chi-Tung Cheng, et al.
Oncotarget|May 7, 2014
Antitumor activity of the combination of an HSP90 inhibitor and a PI3K/mTOR dual inhibitor against cholangiocarcinomaMing-Huang Chen, Kun-Chun Chiang, Chi-Tung Cheng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 18, 2022
Impaired Chromatin Remodeling Predicts Better Survival to Modified Gemcitabine and S-1 plus Nivolumab in Advanced Biliary Tract Cancer: A Phase II T1219 StudyNai-Jung Chiang, Kien Thiam Tan, Li-Yuan Bai, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|September 17, 2025
FGFR2 Fusions or Rearrangements in Young Intrahepatic and Perihilar Cholangiocarcinoma Patients: Key Genetic Insights From a Pan-Asian StudyYuta Maruki, Yasushi Yatabe, Chiharu Mizoguchi, et al.
Cancers|January 11, 2022
Microsatellite Instability, Epstein-Barr Virus, and Programmed Cell Death Ligand 1 as Predictive Markers for Immunotherapy in Gastric CancerHung-Yuan Yu, Chung-Pin Li, Yi-Hsiang Huang, et al.
Cancer|August 20, 2025
Clinical outcomes of gastroenteropancreatic neuroendocrine neoplasms in Taiwan: A multicenter registry study-TCOG T1214 studyHui-Jen Tsai, Ming-Huang Chen, Hsiu-Po Wang, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 1, 2025
Carbon ion therapy for pancreatic cancer with risk-adapted dose escalation: initial clinical experienceI-Chun Lai, Yu-Mei Kang, Yuan-Hung Wu, et al.
Pageof 19

Showing results (171-180 of 183) with videos related to

Sort By:
Pageof 19
Journal of Molecular Medicine (Berlin, Germany)|June 5, 2017
Sequential combination of docetaxel with a SHP-1 agonist enhanced suppression of p-STAT3 signaling and apoptosis in triple negative breast cancer cellsChun-Yu Liu, Kuen-Feng Chen, Tzu-I Chao, et al.
Journal for Immunotherapy of Cancer|April 3, 2020
<i>PRKDC</i>: new biomarker and drug target for checkpoint blockade immunotherapyKien Thiam Tan, Chun-Nan Yeh, Yu-Chan Chang, et al.
EJNMMI Research|May 24, 2019
A phase 0 study of the pharmacokinetics, biodistribution, and dosimetry of <sup>188</sup>Re-liposome in patients with metastatic tumorsShyh-Jen Wang, Wen-Sheng Huang, Chi-Mu Chuang, et al.
Oncotarget|June 20, 2015
Identification of SPHK1 as a therapeutic target and marker of poor prognosis in cholangiocarcinomaMing-Huang Chen, Chueh-Chuan Yen, Chi-Tung Cheng, et al.
Oncotarget|May 7, 2014
Antitumor activity of the combination of an HSP90 inhibitor and a PI3K/mTOR dual inhibitor against cholangiocarcinomaMing-Huang Chen, Kun-Chun Chiang, Chi-Tung Cheng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 18, 2022
Impaired Chromatin Remodeling Predicts Better Survival to Modified Gemcitabine and S-1 plus Nivolumab in Advanced Biliary Tract Cancer: A Phase II T1219 StudyNai-Jung Chiang, Kien Thiam Tan, Li-Yuan Bai, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|September 17, 2025
FGFR2 Fusions or Rearrangements in Young Intrahepatic and Perihilar Cholangiocarcinoma Patients: Key Genetic Insights From a Pan-Asian StudyYuta Maruki, Yasushi Yatabe, Chiharu Mizoguchi, et al.
Cancers|January 11, 2022
Microsatellite Instability, Epstein-Barr Virus, and Programmed Cell Death Ligand 1 as Predictive Markers for Immunotherapy in Gastric CancerHung-Yuan Yu, Chung-Pin Li, Yi-Hsiang Huang, et al.
Cancer|August 20, 2025
Clinical outcomes of gastroenteropancreatic neuroendocrine neoplasms in Taiwan: A multicenter registry study-TCOG T1214 studyHui-Jen Tsai, Ming-Huang Chen, Hsiu-Po Wang, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 1, 2025
Carbon ion therapy for pancreatic cancer with risk-adapted dose escalation: initial clinical experienceI-Chun Lai, Yu-Mei Kang, Yuan-Hung Wu, et al.
Pageof 19